Wall Street analysts expect Medidata Solutions Inc (NASDAQ:MDSO) to report earnings per share (EPS) of $0.31 for the current quarter, Zacks reports. Six analysts have issued estimates for Medidata Solutions’ earnings. The lowest EPS estimate is $0.25 and the highest is $0.38. Medidata Solutions posted earnings per share of $0.33 during the same quarter last year, which indicates a negative year-over-year growth rate of 6.1%. The business is scheduled to issue its next earnings results on Thursday, February 8th.

According to Zacks, analysts expect that Medidata Solutions will report full-year earnings of $1.27 per share for the current fiscal year, with EPS estimates ranging from $1.21 to $1.34. For the next financial year, analysts forecast that the company will post earnings of $1.46 per share, with EPS estimates ranging from $1.31 to $1.61. Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that follow Medidata Solutions.

Medidata Solutions (NASDAQ:MDSO) last released its quarterly earnings data on Thursday, October 26th. The company reported $0.33 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.02. Medidata Solutions had a return on equity of 11.54% and a net margin of 7.84%. The company had revenue of $140.08 million during the quarter, compared to the consensus estimate of $141.27 million. During the same quarter in the prior year, the firm posted $0.28 earnings per share. The firm’s revenue was up 16.7% compared to the same quarter last year.

Several research analysts have recently issued reports on MDSO shares. Royal Bank of Canada reaffirmed a “hold” rating and issued a $80.00 price objective on shares of Medidata Solutions in a research note on Friday, October 27th. Zacks Investment Research downgraded Medidata Solutions from a “hold” rating to a “sell” rating in a research note on Wednesday, December 27th. BidaskClub raised Medidata Solutions from a “sell” rating to a “hold” rating in a research note on Tuesday, January 16th. Deutsche Bank started coverage on Medidata Solutions in a research note on Friday, December 8th. They issued a “buy” rating and a $78.00 price objective for the company. Finally, TheStreet downgraded Medidata Solutions from a “b” rating to a “c+” rating in a research note on Thursday, December 14th. One research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $84.54.

In other Medidata Solutions news, CFO Rouven Bergmann sold 2,000 shares of the stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $65.40, for a total transaction of $130,800.00. Following the transaction, the chief financial officer now directly owns 91,775 shares in the company, valued at approximately $6,002,085. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Michael I. Otner sold 10,000 shares of the stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $70.88, for a total value of $708,800.00. Following the transaction, the executive vice president now owns 80,674 shares in the company, valued at $5,718,173.12. The disclosure for this sale can be found here. Insiders sold 241,010 shares of company stock worth $16,569,956 over the last quarter. 5.80% of the stock is currently owned by company insiders.

Several institutional investors have recently bought and sold shares of the business. Fortaleza Asset Management Inc. bought a new position in shares of Medidata Solutions in the 3rd quarter worth $155,000. Polen Capital Management LLC purchased a new stake in shares of Medidata Solutions during the 3rd quarter valued at $205,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Medidata Solutions during the 2nd quarter valued at $227,000. ETF Managers Group LLC purchased a new stake in shares of Medidata Solutions during the 2nd quarter valued at $233,000. Finally, Hanseatic Management Services Inc. increased its position in shares of Medidata Solutions by 14,915.0% during the 3rd quarter. Hanseatic Management Services Inc. now owns 3,003 shares of the company’s stock valued at $234,000 after purchasing an additional 2,983 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Medidata Solutions (NASDAQ MDSO) traded up $0.16 during trading on Friday, hitting $67.02. The stock had a trading volume of 797,600 shares, compared to its average volume of 473,821. Medidata Solutions has a one year low of $47.77 and a one year high of $85.92. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.29 and a quick ratio of 3.37. The firm has a market capitalization of $4,070.00, a P/E ratio of 95.74, a P/E/G ratio of 3.46 and a beta of 1.69.

COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Expect Medidata Solutions Inc (MDSO) Will Announce Earnings of $0.31 Per Share” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this story can be viewed at https://www.thecerbatgem.com/2018/01/23/zacks-analysts-expect-medidata-solutions-inc-mdso-will-announce-earnings-of-0-31-per-share.html.

About Medidata Solutions

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.

Get a free copy of the Zacks research report on Medidata Solutions (MDSO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.